Climb Bio (CLYM) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio (CLYM) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 549.1% versus a loss of 31.4%. Over five years, DBVT leads with a -7.8% price change compared with -33.6% for CLYM. Climb Bio is the larger company by market cap ($615.1 million vs $614.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | DBVT |
|---|---|---|
| Share price | $10.71 | $9.77 |
| Market cap | $615.14M | $614.03M |
| 1-day change | +0.28% | -2.10% |
| YTD return | +167.75% | -49.03% |
| 1-year return | +549.09% | -31.39% |
| 5-year return | -33.64% | -7.83% |
| EPS (TTM) | $-0.82 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $26.19 |
| 52-week low | $1.64 | $9.64 |
| Distance from 52-week high | -41.57% | -62.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +157.42% | +295.39% |
| Average volume | 1.39M | 328.30K |
| Shares outstanding | 57.44M | 62.85M |
| Employees | 28 | 170 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed DBVT by 580.5 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Healthcare · Biotechnology · 28 employees
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
CLYM vs DBVT FAQ
Which is bigger, Climb Bio or DBV Technologies S.A.?
Climb Bio (CLYM) is larger, with a market capitalization of $615.14M compared with $614.03M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, CLYM or DBVT?
CLYM returned +549.09% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.